Focus: The pharmaceutical innovation dilemmaSolving today’s R&D productivity challenge |
Pharmaceutical innovation is facing a fundamental productivity challenge. Investment in research and development (R&D) has outpaced sales growth, but this has not increased output of new medicines. Pharmaceutical executives are seeking greater transparency in R&D decision making against a backdrop of rising hurdles for regulatory approval and reimbursement.
Despite the ever-intensifying attention these problems are receiving, the solutions that have been proposed, and in some cases implemented, have not gained broad traction or shown clear success. So how are industry executives approaching these innovation challenges?
This series of articles addresses multiple business areas and outlines innovative and distinctive solutions to current and potential industry challenges. Each article represents a snapshot of Deloitte's point of view and is intended to foster further thinking and conversation regarding innovation and R&D issues.
Contact the Life Sciences and Health Care industry group to learn more about Deloitte's global industry practice.
Featured content
 |
Measuring the return from innovation: Is R&D earning its investment? Against a backdrop of rising costs and declining output, R&D leaders in the life sciences industry are under continued pressure to justify the investment in R&D. The new Deloitte U.K. Center for Health Solutions and Thomson Reuters collaborated in producing this annual review of R&D returns in life sciences. |
Related content
 |
Financial Times Pharma & Biotech conference 2011 – 5-6 December, London Jointly developed by the FT and Deloitte, this leading industry event brings together industry executives, government decision makers, investors, analysts, and other specialist providers to explore today's most pressing issues. |
 |
The next phase: Opportunities in China's pharmaceuticals market This Deloitte China report focuses on pharmaceuticals companies, both domestic and foreign, and their activities in the China market—all from the viewpoint of prospective investors. |
 |
R&D leadership development in today's environment R&D leadership today requires something even more important than business skills and competencies. Leaders need to be able to think strategically to understand the organization's overall strategic direction as well as to help chart it. They must understand the 'business of science'. |
 |
2011 global survey of health care consumers Explore the findings from Deloitte's fourth consumer survey, based on the findings from 15,000 consumers in 12 countries. See how economic uncertainty and skyrocketing costs are affecting consumer behavior. |
 |
Case study: When a powerhouse pharmaceutical made a major acquisition Business analytics and a custom accounting tool facilitated the accounting of adjustments during an acquisition and resulted in the efficient and effective control of the purchase. |
Additional Resources
 |
Creating a new formula for drug safety and compliance Blending the synergies of its leading life sciences R&D practice with a drug safety consulting market leader, Deloitte has acquired Intrasphere, a global drug safety and regulatory consulting business. |
 |
U.S. Health Reform Health reform's indirect impacts related to the changing nature of their relationships to other stakeholders, could demonstrate an even greater catalyst for transformation. |
